HRP20220368T1 - Pripravci entereococcus flagellin za uporabu u liječenju - Google Patents
Pripravci entereococcus flagellin za uporabu u liječenju Download PDFInfo
- Publication number
- HRP20220368T1 HRP20220368T1 HRP20220368TT HRP20220368T HRP20220368T1 HR P20220368 T1 HRP20220368 T1 HR P20220368T1 HR P20220368T T HRP20220368T T HR P20220368TT HR P20220368 T HRP20220368 T HR P20220368T HR P20220368 T1 HRP20220368 T1 HR P20220368T1
- Authority
- HR
- Croatia
- Prior art keywords
- flagellin polypeptide
- polypeptide
- seq
- preparation
- treatment
- Prior art date
Links
- 108010040721 Flagellin Proteins 0.000 title claims 27
- 239000000203 mixture Substances 0.000 title claims 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims 32
- 102000004196 processed proteins & peptides Human genes 0.000 claims 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims 32
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 9
- 241000194033 Enterococcus Species 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 5
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 3
- 230000004927 fusion Effects 0.000 claims 3
- 230000001717 pathogenic effect Effects 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 241000194030 Enterococcus gallinarum Species 0.000 claims 1
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 102000003945 NF-kappa B Human genes 0.000 claims 1
- 108010057466 NF-kappa B Proteins 0.000 claims 1
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 239000012646 vaccine adjuvant Substances 0.000 claims 1
- 229940124931 vaccine adjuvant Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (15)
1. Flagelinski polipeptid iz roda Enterococcus, naznačen time, da je za uporabu u liječenju.
2. Flagelinski polipeptid za uporabu prema patentnom zahtjevu 1, naznačen time, da:
a) flagelinski polipeptid je od vrste Enterococcus gallinarum; i/ili
b) flagelinski polipeptid potječe iz soja koji je deponiran u NCIMB pod pristupnim brojem NCIMB 42488; i/ili
c) flagelinski polipeptid ne sadrži D3 domenu; i/ili
d) flagelinski polipeptid je u monomernom obliku; i/ili
e) flagelinski polipeptid sadrži TLR5 mjesto prepoznavanja koje je najmanje 99%, 99,5% ili 99,9% istovjetno ostacima 87-96 i 290-295 u SEQ ID NO: 1; i/ili
f) flagelinski polipeptid je dio bakterijske flagelarne skupine.
3. Flagelinski polipeptid za uporabu prema bilo kojem prethodnom patentnom zahtjevu, naznačen time, da flagelinski polipeptid:
(a) ima slijed koji je najmanje 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99,5% ili 99,9% istovjetan slijedu SEQ ID NO: 1; ili
(b) ima slijed koji je najmanje 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99,5% ili 99,9% istovjetan slijedu SEQ ID NO: 2; ili
(c) ima slijed koji je najmanje 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99,5% ili 99,9% istovjetan jednom od sljedova SEQ ID NO: 3-42, pri čemu opcionalno flagelinski polipeptid ima slijed koji je najmanje 95%, 96%, 97%, 98%, 99%, 99,5% ili 99,9% istovjetan jednom od sljedova SEQ ID NO: 3-16; ili
(d) time, da flagelinski polipeptid sadrži SEQ ID NO: 1, ili SEQ ID NO: 2.
4. Fragment flagelinskog polipeptida iz roda Enterococcus, za uporabu u liječenju, naznačen time, da fragment sadrži aminokiseline 87-96, 165-272 i 290-295 iz SEQ ID NO: 1; dok opcionalno pritom
a) fragment sadrži aminokiseline 2-32, 87-96, 165-272, 234-358, 290-295 iz SEQ ID NO: 1; i/ili
b) fragment je u duljini od 200, 250, 300 ili 350 aminokiselina; i/ili
c) fragment ima slijed koji je najmanje 85% istovjetan slijedu SEQ ID NO: 1; i/ili
d) flagelinski polipeptid je definiran prema bilo kojem od patentnih zahtjeva 1 do 3.
5. Flagelinski polipeptid za uporabu prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da je konjugiran na antigen, kao što je patogeni antigen ili tumorski antigen.
6. Fuzijski polipeptid, naznačen time, da sadrži flagelinski polipeptid za uporabu u liječenju, pri čemu je flagelinski polipeptid definiran prema bilo kojem od patentnih zahtjeva 1 do 5; gdje fuzijski polipeptid opcionalno sadrži antigen, kao što je patogeni antigen ili tumorski antigen.
7. Farmaceutski pripravak, naznačen time, da sadrži fragment flagelinskog polipeptida iz roda Enterococcus, pri čemu fragment
a) sadrži aminokiseline 87-96, 165-272 i 290-295 iz SEQ ID NO: 1, i jedan ili više farmaceutski prihvatljivih pomoćnih sredstava ili nosača; ili
b) sadrži aminokiseline 2-32, 87-96, 165-272, 234-358, 290-295 iz SEQ ID NO: 1, i jedan ili više farmaceutski prihvatljivih pomoćnih sredstava ili nosača.
8. Fragment flagelinskog polipeptida ili farmaceutski pripravak za uporabu prema bilo kojem prethodnom patentnom zahtjevu, naznačen time, da:
a) polipeptid je dio bakterijskog flagelarnog sastava; i/ili
b) polipeptid dodatno sadrži jedan ili više antigena.
9. Polinukleotidni slijed koji kodira flagelinski polipeptid iz roda Enterococcus, naznačen time, da je za uporabu u liječenju; pri čemu je opcionalno flagelinski polipeptid definiran prema bilo kojem od patentnih zahtjeva 2 do 5; te time, da je opcionalno nadalje kodirani polipeptidni slijed najmanje 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99,5% ili 99,9% istovjetan slijedu SEQ ID NO: 1, ili on jest SEQ ID NO: 1.
10. Stanica domaćina, naznačena time, da:
a) eksprimira rekombinantni flagelinski polipeptid iz roda Enterococcus, za uporabu u liječenju; ili
b) sadrži rekombinantni polinukleotidni slijed koji kodira flagelinski polipeptid iz roda Enterococcus, za uporabu u liječenju;
dok je opcionalno pritom flagelinski polipeptid definiran prema bilo kojem od patentnih zahtjeva 2 do 9.
11. Vektor ili plazmid, naznačen time, da sadrži polinukleotidni slijed prema patentnom zahtjevu 9.
12. Stanica domaćina, naznačena time, da sadrži vektor ili plazmid prema patentnom zahtjevu 11; pri čemu opcionalno stanica domaćina dodatno eksprimira heterologni antigen, kao što je patogeni antigen ili tumorski antigen.
13. Pripravak za uporabu u liječenju, naznačen time, da pripravak sadrži flagelinski polipeptid prema bilo kojem od patentnih zahtjeva 1 do 4, fragment flagelinskog polipeptida prema patentnom zahtjevu 5, fuzijski polipeptid prema patentnom zahtjevu 7, polinukleotid prema patentnom zahtjevu 10, stanicu domaćina prema bilo kojem od patentnih zahtjeva 11 i 13, ili vektor prema patentnom zahtjevu 12.
14. Pripravak za uporabu prema patentnom zahtjevu 13, naznačen time, da je za uporabu u postupku liječenja ili prevencije raka; pri čemu opcionalno
a) pripravak je za uporabu u liječenju imunogenskih tumora; i/ili
b) pripravak je za uporabu u postupku liječenja ili prevencije raka pluća, raka dojke, raka jetre ili raka debelog crijeva; i/ili
c) pripravak je za uporabu u postupku smanjivanja veličine tumora, smanjivanja rasta tumora, prevencije metastaza ili prevencije angiogeneza.
15. Pripravak za uporabu prema patentnom zahtjevu 14, naznačen time, da je
a) za uporabu u liječenju, prevenciji ili odgađanju imunosenescencije; ili
b) za uporabu kao adjuvanta za cjepivo; ili
c) za uporabu kod poboljšanja stanične terapije; kao što je CAR-T,
pri čemu opcionalno
i) pripravak povećava razinu i/ili aktivnost NF-κB; i/ili
ii) pripravak je za oralnu primjenu; i/ili
iii) pripravak sadrži jedno ili više farmaceutski prihvatljivih pomoćnih sredstava ili nosača.
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1804384.4A GB201804384D0 (en) | 2018-03-19 | 2018-03-19 | Compositions |
| GBGB1809953.1A GB201809953D0 (en) | 2018-06-18 | 2018-06-18 | Compositions |
| EP18178350 | 2018-06-18 | ||
| GBGB1811900.8A GB201811900D0 (en) | 2018-07-20 | 2018-07-20 | Compositions comprising bacterial strains |
| GBGB1812378.6A GB201812378D0 (en) | 2018-07-30 | 2018-07-30 | Compositions comprising bacterial strains |
| GBGB1813423.9A GB201813423D0 (en) | 2018-08-17 | 2018-08-17 | Compositions comprising bacterial strains |
| GBGB1813444.5A GB201813444D0 (en) | 2018-08-17 | 2018-08-17 | Compositions |
| GBGB1816834.4A GB201816834D0 (en) | 2018-10-16 | 2018-10-16 | Compositions |
| GBGB1817641.2A GB201817641D0 (en) | 2018-10-29 | 2018-10-29 | Compositions comprising bacterial strains |
| GBGB1901199.8A GB201901199D0 (en) | 2019-01-29 | 2019-01-29 | Compositions comprising bacterial strains |
| GBGB1901218.6A GB201901218D0 (en) | 2019-01-29 | 2019-01-29 | Compositions |
| GBGB1901993.4A GB201901993D0 (en) | 2019-02-13 | 2019-02-13 | Compositions |
| GBGB1901992.6A GB201901992D0 (en) | 2019-02-13 | 2019-02-13 | Compositions comprising bacterial strains |
| PCT/EP2019/056809 WO2019180000A1 (en) | 2018-03-19 | 2019-03-19 | Compositions |
| EP19714132.8A EP3768284B1 (en) | 2018-03-19 | 2019-03-19 | Compositions of entrecoccus flagellin for use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220368T1 true HRP20220368T1 (hr) | 2022-06-24 |
Family
ID=65955185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220368TT HRP20220368T1 (hr) | 2018-03-19 | 2019-03-19 | Pripravci entereococcus flagellin za uporabu u liječenju |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11419931B2 (hr) |
| EP (3) | EP3768284B1 (hr) |
| JP (3) | JP2021518129A (hr) |
| KR (2) | KR102578117B1 (hr) |
| CN (2) | CN111886018A (hr) |
| AU (2) | AU2019238358A1 (hr) |
| BR (2) | BR112020019008A2 (hr) |
| CA (2) | CA3094139A1 (hr) |
| CY (1) | CY1125104T1 (hr) |
| DK (1) | DK3768284T3 (hr) |
| ES (1) | ES2908826T3 (hr) |
| HR (1) | HRP20220368T1 (hr) |
| HU (1) | HUE058151T2 (hr) |
| IL (2) | IL277421B (hr) |
| LT (1) | LT3768284T (hr) |
| MA (1) | MA52128A (hr) |
| MD (1) | MD3768284T2 (hr) |
| MX (2) | MX2020009736A (hr) |
| PL (1) | PL3768284T3 (hr) |
| RS (1) | RS63090B1 (hr) |
| SG (2) | SG11202009254YA (hr) |
| SI (1) | SI3768284T1 (hr) |
| TW (2) | TW202003000A (hr) |
| WO (2) | WO2019180000A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019238358A1 (en) | 2018-03-19 | 2020-10-08 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US20230022045A1 (en) * | 2019-12-03 | 2023-01-26 | Board Of Regents, The University Of Texas System | Combination therapies for the treatment of cancer |
| WO2021252632A2 (en) * | 2020-06-09 | 2021-12-16 | Flagship Pioneering, Inc. | Physiologically acceptable compositions containing microorganisms or microbial products |
| WO2023060279A1 (en) * | 2021-10-08 | 2023-04-13 | Iowa State University Research Foundation, Inc. | Use of dopamine producing products to increase vaccine efficacy |
| CN113999923B (zh) * | 2021-11-25 | 2024-05-14 | 上海金翌生物科技有限公司 | 小柳-原田综合症标志微生物及其应用 |
| CN115287243B (zh) * | 2022-04-15 | 2023-06-06 | 集美大学 | 一株变形假单胞菌flgK基因沉默菌株及其构建方法 |
| WO2024096122A1 (ja) * | 2022-11-04 | 2024-05-10 | 株式会社バイオパレット | Ｔｏｌｌ－Ｌｉｋｅ Ｒｅｃｅｐｔｏｒ ５（ＴＬＲ５）の活性化能を調節する微生物およびその生産方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
| US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| JPH08259450A (ja) | 1995-03-17 | 1996-10-08 | Nichinichi Seiyaku Kk | インターフェロン産生増強剤 |
| US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
| EP0904784A1 (en) | 1997-09-22 | 1999-03-31 | N.V. Nutricia | Probiotic nutritional preparation |
| GB0127916D0 (en) | 2001-11-21 | 2002-01-16 | Rowett Res Inst | Method |
| US20040009937A1 (en) * | 2002-01-31 | 2004-01-15 | Wei Chen | Methods and composition for delivering nucleic acids and/or proteins to the respiratory system |
| US20080025977A1 (en) | 2003-04-14 | 2008-01-31 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD59 |
| US20060228369A1 (en) | 2005-04-11 | 2006-10-12 | Program For Appropriate Technology In Health | Stabilization and preservation of temperature-sensitive vaccines |
| JP2007116991A (ja) | 2005-10-28 | 2007-05-17 | Eternal Light General Institute Inc | 機能性食品 |
| KR101170283B1 (ko) | 2006-10-27 | 2012-07-31 | 화이자 프로덕츠 인코포레이티드 | 하이드록시프로필 메틸 셀룰로스 경질 캡슐 및 이의 제조 방법 |
| EP1958647A1 (en) | 2007-02-15 | 2008-08-20 | Helmholtz-Zentrum für Infektionsforschung GmbH | Pharmaceutical composition with bacteria for tumor treatment |
| EP2133092B1 (en) | 2007-03-19 | 2015-12-09 | Morishita Jintan Co., Ltd. | Oral vaccine |
| CN102046198A (zh) * | 2008-04-25 | 2011-05-04 | 系统生物学研究所 | 鞭毛蛋白多肽疫苗 |
| EA021842B1 (ru) | 2009-10-06 | 2015-09-30 | Общество С Ограниченной Ответственностью "Панацела Лабс" | Применение toll-подобного рецептора и агониста для лечения рака |
| SG191830A1 (en) | 2011-01-10 | 2013-08-30 | Cleveland Biolabs Inc | Use of toll-like receptor agonist for treating cancer |
| EP2731572B1 (en) | 2011-07-13 | 2021-04-07 | Pharmaxis Ltd. | Improvements relating to delivery devices |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| ES2408279B1 (es) | 2011-12-15 | 2014-09-09 | Universidad De Las Palmas De Gran Canaria | Bacteria acido láctica probiótica |
| FR2989002B1 (fr) | 2012-04-10 | 2015-05-15 | Beepratte Lab | Compositions a base de probiotiques et d'un complexe beepollen/argile, leur preparation et leurs utilisations en nutrition et therapeutique |
| CA2884816A1 (en) | 2012-09-13 | 2014-03-20 | Massachusetts Institute Of Technology | Programmable drug delivery profiles of tumor-targeted bacteria |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| CA2935635C (en) * | 2014-02-12 | 2023-05-09 | Transalgae Israel Ltd. | Algal based edible vaccines |
| MD3209310T2 (ro) | 2015-11-20 | 2018-06-30 | 4D Pharma Res Ltd | Compoziții care conțin tulpini bacteriene |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520502D0 (en) * | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| MA41708A (fr) * | 2017-05-24 | 2020-04-08 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| AR112328A1 (es) | 2017-07-05 | 2019-10-16 | Evelo Biosciences Inc | Composiciones y métodos para tratamiento de cáncer usando bifidobacterium animalis ssp. lactis |
| CN111246866A (zh) | 2017-08-10 | 2020-06-05 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
| AU2019238358A1 (en) | 2018-03-19 | 2020-10-08 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
-
2019
- 2019-03-19 AU AU2019238358A patent/AU2019238358A1/en not_active Abandoned
- 2019-03-19 BR BR112020019008-0A patent/BR112020019008A2/pt not_active Application Discontinuation
- 2019-03-19 MX MX2020009736A patent/MX2020009736A/es unknown
- 2019-03-19 HU HUE19714132A patent/HUE058151T2/hu unknown
- 2019-03-19 KR KR1020207029431A patent/KR102578117B1/ko active IP Right Grant
- 2019-03-19 PL PL19714132T patent/PL3768284T3/pl unknown
- 2019-03-19 AU AU2019239048A patent/AU2019239048B2/en active Active
- 2019-03-19 CN CN201980020532.2A patent/CN111886018A/zh active Pending
- 2019-03-19 WO PCT/EP2019/056809 patent/WO2019180000A1/en active Search and Examination
- 2019-03-19 ES ES19714132T patent/ES2908826T3/es active Active
- 2019-03-19 TW TW108109387A patent/TW202003000A/zh unknown
- 2019-03-19 RS RS20220288A patent/RS63090B1/sr unknown
- 2019-03-19 EP EP19714132.8A patent/EP3768284B1/en active Active
- 2019-03-19 CA CA3094139A patent/CA3094139A1/en not_active Abandoned
- 2019-03-19 JP JP2020550598A patent/JP2021518129A/ja active Pending
- 2019-03-19 MD MDE20210096T patent/MD3768284T2/ro unknown
- 2019-03-19 TW TW108109417A patent/TW202003001A/zh unknown
- 2019-03-19 JP JP2020550823A patent/JP2021518414A/ja active Pending
- 2019-03-19 DK DK19714132.8T patent/DK3768284T3/da active
- 2019-03-19 MX MX2020009733A patent/MX2020009733A/es unknown
- 2019-03-19 EP EP19714136.9A patent/EP3768285A1/en active Pending
- 2019-03-19 KR KR1020207028232A patent/KR20210003096A/ko unknown
- 2019-03-19 MA MA052128A patent/MA52128A/fr unknown
- 2019-03-19 SG SG11202009254YA patent/SG11202009254YA/en unknown
- 2019-03-19 CN CN201980026687.7A patent/CN112004543A/zh active Pending
- 2019-03-19 CA CA3094297A patent/CA3094297A1/en active Pending
- 2019-03-19 BR BR112020018818-2A patent/BR112020018818A2/pt not_active IP Right Cessation
- 2019-03-19 HR HRP20220368TT patent/HRP20220368T1/hr unknown
- 2019-03-19 SG SG11202009259VA patent/SG11202009259VA/en unknown
- 2019-03-19 SI SI201930190T patent/SI3768284T1/sl unknown
- 2019-03-19 WO PCT/EP2019/056894 patent/WO2019180051A1/en unknown
- 2019-03-19 EP EP22150203.2A patent/EP4046644A1/en active Pending
- 2019-03-19 LT LTEPPCT/EP2019/056809T patent/LT3768284T/lt unknown
-
2020
- 2020-09-16 IL IL277421A patent/IL277421B/en unknown
- 2020-09-16 IL IL277422A patent/IL277422A/en unknown
- 2020-09-17 US US17/024,628 patent/US11419931B2/en active Active
- 2020-09-18 US US17/025,706 patent/US11857614B2/en active Active
-
2022
- 2022-02-24 US US17/679,243 patent/US20220257745A1/en not_active Abandoned
- 2022-03-23 CY CY20221100232T patent/CY1125104T1/el unknown
-
2023
- 2023-04-26 JP JP2023072015A patent/JP2023100747A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220368T1 (hr) | Pripravci entereococcus flagellin za uporabu u liječenju | |
| US7635479B2 (en) | Composition and methods for enhancing immunogenecity of antigens | |
| US6767542B2 (en) | Compositions and methods for enhancing immunogenicity of antigens | |
| HRP20220578T1 (hr) | Pripravci koji sadrže bakterijske sojeve | |
| RU2016145464A (ru) | Рекомбинантные вакцинные штаммы listeria и способы их получения | |
| US20110159026A1 (en) | Compositions and methods of enhancing immune responses to flagellated bacterium | |
| JP2013518052A5 (hr) | ||
| RU2011110376A (ru) | Эпитопные пептиды hig2 и urlc10 и содержание их вакцины | |
| IL276661B2 (en) | Immunogenic preparation containing staphylococcal antigens | |
| WO2019006401A3 (en) | LISTERIA-BASED IMMUNOGENIC COMPOSITIONS COMPRISING HETERICCLIENT WILMS TUMOR PROTEIN ANTIGENS AND METHODS OF USE THEREOF | |
| RU2010154101A (ru) | Пептиды эпитопов mybl2 и содержащие их вакцины | |
| JP2014139185A5 (hr) | ||
| JP2015529677A5 (hr) | ||
| Yang et al. | Alleviation of enterotoxigenic Escherichia coli challenge by recombinant Lactobacillus plantarum expressing a FaeG-and DC-targeting peptide fusion protein | |
| HRP20191864T1 (hr) | Imunogeni pripravci protiv bakterije clostridium difficile | |
| JP2021512966A5 (hr) | ||
| Lu et al. | Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope | |
| Di-Qiu et al. | Construction and characterization of Lactobacillus pentosus expressing the D antigenic site of the spike protein of Transmissible gastroenteritis virus | |
| JPWO2019180000A5 (hr) | ||
| PH12020500194A1 (en) | Malaria vaccine | |
| MX2021004907A (es) | Vacuna de ibv 4/91 con proteina espicular heterologa. | |
| Ji et al. | Construction and immunological evaluation of live vector vaccine based on attenuated Listeria monocytogenes vector against Vibrio parahaemolyticus infection | |
| RU2021109510A (ru) | Вакцинация с использованием альфа 3 домена mica/b для лечения рака | |
| CA2945925C (en) | Particulate vaccine formulations for inducing innate and adaptive immunity | |
| Liang et al. | Immunogenicity and therapeutic effects of recombinant Ag85AB fusion protein vaccines in mice infected with Mycobacterium tuberculosis |